This is why Dr. Yuling Wang is so excited by results of a trial completed in late 2019, which—using plasmonic nanoparticles developed by the Centre for Nanoscale BioPhotonics (CNBP)—successfully detected signs of the cancer in blood of patients undergoing treatment. The paper was recently published in the journal American Chemical Society—Sensors. Read more . . .